Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Apeptico Forschung und Entwicklung GmbH. (10/23/13). "Press Release: Apeptico Announces a Licensing Agreement for Pepbase with Chem Tech Research Incorporation (C-TRI)". Vienna.

Organisations Organisation Apeptico Forschung und Entwicklung GmbH
  Organisation 2 Chem Tech Research Inc. (C-TRI)
Products Product Pepbase™ therapeutic protein database
  Product 2 drug development
Index term Index term Chem Tech Research–Apeptico: proteomic database, 201310– license to Pepbase therapeutic protein database for C-TRI
Persons Person Fischer, Bernhard (Apeptico 200903 CEO)
  Person 2 Kim, Wan-joo (Chem Tech Research 201310 CEO)
     


APEPTICO, a privately-held biotechnology company developing peptide drugs, today announced that it has entered into a license agreement with Chem Tech Research Incorporation (C-TRI), where APEPTICO will provide C-TRI with a non-exclusive license to APEPTICO's database PEPBASE(TM). Under terms of the Agreement, APEPTICO will receive a license fee and annual payments from C-TRI for data base updates.

APEPTICO (Vienna, Austria) is a clinical stage biotechnology company in Austria that develops new peptide-based medicinal products for therapeutic and prophylactic treatment of various severe forms of pulmonary oedema. C-TRI (Seoul, Korea) is a research-oriented pharma company which focuses on developing new drugs and medicines.

PEPBASE(TM) is a unique research database of human therapeutic proteins. The protein therapeutics included in PEPBASE(TM) are manufactured by recombinant DNA technology and have received marketing authorisation in the EU or US for medicinal use in humans. For each protein a specific profile is established, based on preclinical and clinical data, supported by structural, functional and biochemical data, in an attempt to link structural and therapeutically relevant properties on a single platform. As a consequence of this strategy, therapeutic peptides which mimic functional domains of these human proteins are also described in PEPBASE(TM). Protein profiles also include developmental, manufacturing and regulatory information.

"We are very pleased to enter into this agreement with C-TRI, a Korean leader in peptide chemistry and biotechnology", stated Bernhard Fischer, Chief Executive Officer of APEPTICO. "APEPTICO's database PEPBASE(TM) represents an unique research tool for C-TRI and will make a significant contribution to our new drug development program" commented Kim Wan-joo, Chief Executive Officer of C-TRI.


About APEPTICO GmbH (www.apeptico.com)

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.


About C-TRI (http://www.c-tri.co.kr)

C-TRI is a research-oriented pharmaceutical company which has focused on developing new drugs and medicines ever since its establishment in 1998. The company vision is to become the number one company in Korea in life science. C-TRI is actively growing in next-generation peptide drugs, anti-viral drugs and ionic liquids.


About PEPBASE(TM)

PEPBASE(TM) is APEPTICO's a unique database of human therapeutic proteins. The protein therapeutics included in PEPBASE(TM) are manufactured by recombinant DNA technology and have received marketing authorisation in the EU or US for medicinal use in humans. For each protein a specific profile is established, based on preclinical and clinical data, supported by structural, functional and biochemical data, in an attempt to link structural and therapeutically relevant properties on a single platform. As a consequence of this strategy, therapeutic peptides which mimic functional domains of these human proteins are also described in PEPBASE(TM). Protein profiles also include developmental, manufacturing and regulatory information.


Contact

Univ.- Doz. Dr. Bernhard Fischer, Chief Executive Officer
APEPTICO Forschung und Entwicklung GmbH
Mariahilferstraße 136, Top 1.15, A-1150 Vienna, Austria
Mail: b.fischer@apeptico.com
URL: www.apeptico.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Apeptico Forschung und Entwicklung GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top